MCIA
VRTX icon

Mountain Capital Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Mountain Capital Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-142
Closed -$22K – 417
2017
Q3 		$22K Hold
142
– – 0.02% 178
2017
Q2 		$18K Buy
+142
New +$17.1K 0.02% 231

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Mountain Capital Investment Advisors's VRTX Position: Q4 2017 in Review

Mountain Capital Investment Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2017, closing a stake of 142 shares — an estimated $22K sold.

Mountain Capital Investment Advisors first reported a position in VRTX in Q2 2017 and held it in 2 quarters. The position peaked at $22K in Q3 2017. 644 funds tracked by Wall St. Rank hold VRTX as of Q4 2017.

  • Mountain Capital Investment Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Mountain Capital Investment Advisors sold 142 Vertex Pharmaceuticals shares in Q4 2017, an estimated $22K.
  • Mountain Capital Investment Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Mountain Capital Investment Advisors's Vertex Pharmaceuticals position peaked at $22K in Q3 2017.
  • 644 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2017.

Based on Mountain Capital Investment Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.